Glioblastoma targeted therapy: updated approaches from recent biological insights

Autor Touat, M., Idbaih, A., Sanson, M., Ligon, K. L.
Vydáno v Ann Oncol (2017)

P04.10 Chains of magnetosomes induce full destruction of intracranial U87-Luc and subcutaneous GL-261 glioma in mice under the application of an alternating magnetic field

Autor Alphandery, E, Idbaih, A, Adam, C, Delattre, J, Schmitt, C, Guyot, F, Chebbi, I
Vydáno v Neuro Oncol (2018)

P04.14 IDH1 MUTATION IN LOW-GRADE GLIOMAS RELATED TO EPILEPSY AS INITIAL SYMPTOM

Autor Duran-Peña, A., Mokhtari, K., Marie, Y., Alentorn, A., Delattre, J., Idbaih, A., Sanson, M., Vecht, C.
Vydáno 2014

P17.08 RENAL THROMBOTIC MICROANGIOPATHY INDUCED BY BEVACIZUMAB IN HIGH GRADE GLIOMA PATIENTS - ABOUT SIX CASES

Autor Blonski, M., Simon, L., Houillier, C., Idbaih, A., Wittwer, B., Beauchesne, P., Hoang-Xuan, K., Taillandier, L.
Vydáno 2014

P10.14 Long-term impact of Temozolomide on 1p19q codeleted oligodendrogliomas growth kinetics

Autor Izquierdo, C., Alentorn, A., Simó, M., Idbaih, A., Ricard, D., Kaloshi, G., Bruna, J., Honnorat, J., Delattre, J., Ducray, F.
Vydáno v Neuro Oncol (2017)

OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults

Autor Picart, T, Barritault, M, Tabouret, E, Idbaih, A, Izquierdo Gracia, C, Poncet, D, Honnorat, J, Meyronet, D, Guyotat, J, Ducray, F
Vydáno v Neuro Oncol (2019)

P05.05 Safety and feasibility of temporary blood-brain barrier disruption with the SonoCloud-1/3 implantable ultrasound device in recurrent glioblastoma

Autor Idbaih, A, Canney, M, Bouchoux, G, Desseaux, C, Vignot, A, Lafon, C, Chapelon, J, Delattre, J, Belin, L, Carpentier, A
Vydáno v Neuro Oncol (2019)

OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas

Autor Rosenberg, S., Dehais, C., Ducray, F., Alentron, A., Tanguy, M., De Reyneis, A., Elarouci, N., Figarella-Branger, D., Delattre, J., Idbaih, A.
Vydáno v Neuro Oncol (2017)

EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma

Autor van den Bent, M., Gorlia, T., Bendszus, M., Sahm, F., Domont, J., Idbaih, A., Platten, M., Weller, M., Golfoinopoulos, V., Wick, W.
Vydáno v Neuro Oncol (2016)

P01.148 Intra-tumor heterogeneity analysis of low-grade gliomas. A POLA Network study

Autor Alentorn, A, Labreche, K, Dehais, C, Carpentier, C, Ducray, F, Mokhtari, K, Figarella-Branger, D, Sanson, M, Delattre, J, Idbaih, A
Vydáno v Neuro Oncol (2018)

P06.18 DNA methylation distance score in lower-grade gliomas has prognostic value: a POLA network study

Autor Alentorn, A., Kamoun, A., Ducray, F., Dehais, C., Mokhtari, K., Uro-Coste, E., Figarella-Branger, D., Delattre, J., Idbaih, A., Sanson, M.
Vydáno v Neuro Oncol (2016)

P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study

Autor Alentorn, A., Carpentier, C., Labreche, K., Ducray, F., Dehais, C., Mokhtari, K., Uro-Coste, E., Figarella-Branger, D., Delattre, J., Idbaih, A.
Vydáno v Neuro Oncol (2016)

O10.02 MITOTIC INDEX, MICROVASCULAR PROLIFERATION AND NECROSIS DEFINE THREE GROUPS OF 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMAS ASSOCIATED WITH DIFFERENT GENOMIC ALTERATIONS

Autor Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Ducray, F., Idbaih, A., Network, French POLA
Vydáno 2014

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref...

Autor Frappaz, D., Meyronnet, D., Garin, G., Laigle-Donadey, F., Le Rhun, E., Bonneville-Levard, A., Frenel, J., Idbaih, A., Gourmelon, C., Chinot, O.
Vydáno v Neuro Oncol (2016)

P09.14 Clonal and subclonal evolution of 1p/19q co-deleted oligodendrogliomas

Autor Alentorn, A., Daniau, M., Royer-Perron, L., Labreche, K., Duran-Pena, A., Marie, Y., Hoang-Xuan, K., Sanson, M., Delattre, J., Idbaih, A.
Vydáno v Neuro Oncol (2016)

P11.59 Integrin a5 heterogeneous expression in glioblastoma is related to glioma stem cell subpopulations

Autor Dontenwill, M, Mercier, M, Gillmann, G, Reita, D, Lelong-Rebel, I, Noulet, F, Idbaih, A, Herold-Mende, C, Bagnard, D, Spenlé, C, Martin, S
Vydáno v Neuro Oncol (2019)

OS8.5 How to assess meningioma therapy activity: The CEVOREM independent central review experience

Autor GRAILLON, T, Colin, T, Peyrière, H, Peyre, M, Tabouret, E, Campello, C, Idbaih, A, Boucekine, M, Figarella-Branger, D, Kalamarides, M, Dufour, H, Sanson, M, Chinot, O
Vydáno v Neuro Oncol (2019)

P17.01 CHROMOSOME ARM 9P LOSS OF HETEROZYGOSITY IS A MARKER OF SHORTER SURVIVAL IN 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMA. A POLA NETWORK STUDY

Autor Alentorn, A., Dehais, C., Carpentier, C., Mokhtari, K., Ducray, F., Figarella-Branger, D., Delattre, J., Idbaih, A., (POLA)”, POLA Network “Prise en charge des OLigodendrogliomes Anaplasiques
Vydáno 2014

OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III E...

Autor Taphoorn, M. J. B., Bottomley, A., Coens, C., Reijneveld, J. C., Gorlia, T., Brandes, A. A., Domont, J., Idbaih, A., van den Bent, M. J., Wick, W.
Vydáno v Neuro Oncol (2016)

OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma

Autor Idbaih, A., Clement, P. M., Vos, F. Y. F., Platten, M., Mulholland, P., Taphoorn, M. J. B., Lewis, L., Golfinopoulos, V., Gorlia, T., van den Bent, M. J.
Vydáno v Neuro Oncol (2016)